Arcutis Inc. is using its founders’ topical reformulation expertise to develop safer and less expensive therapeutics against known targets to treat dermatology patients who aren’t eligible for biologics. Frazier Healthcare launched the company in 2016...

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...

INDICATION: Multiple sclerosis (MS) Mouse studies suggest ablating meningeal lymphatic vessels with Visudyne verteporfin could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, injection into the cisterna magna of Visudyne...

Earnings on deck At least 8 profitable biotechs and pharmas are slated to report earnings this week. (A) Formerly Valeant Pharmaceuticals International Inc. Company Date Pre/post mkt 2Q18 EPS est 2Q17 EPS Expected chg Bausch...

The near record-setting pace of 1H18 capital markets activity isn’t likely to be replicated this half, but that won’t be because of changes to sector fundamentals. Instead, it’s likely the consequence of macroeconomic and geopolitical...

Judicious stock picking was especially important in the second quarter, as 57% of global biotech stocks saw their equity values decline. Volatility continued to roil global markets during the period and additional uncertainty looms with...

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...

The Ortho Dermatologics unit of Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) said it received a complete response letter from FDA to an NDA for Duobrii (IDP-118) to treat plaque psoriasis. According to Valeant, FDA had...

Ortho Dermatologics said it received a complete response letter from FDA to an NDA for Duobrii (IDP-118) to treat plaque psoriasis. Ortho parent Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) slid $3.32 (12%) to $23.54 on...

The last five years have seen a steady stream of preclinical deals for antisense, siRNA and mRNA therapies that suggests pharmas are taking the modalities seriously as alternatives to traditional small molecules and antibodies. But...